Renoprotective effect of berberine on type 2 diabetic nephropathy in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 6, 2015, Pages 662-670

  Sun, Si Fan ^a,b   Zhao, Ting Ting ^b   Zhang, Hao Jun ^b   Huang, Xiao Ru ^c   Zhang, Wei Ku ^b   Zhang, Lei ^b   Yan, Mei Hua ^b   Dong, Xi ^b   Wang, Hua ^a,b   Wen, Yu Min ^b   Pan, Xin Ping ^d,e   Lan, Hui Yao ^c   Li, Ping ^a,b  

^a GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d Shanghai Innovation Center of TCM Health Service   (China)

^e Department of Rehabilitation Medicine   (China)

Author keywords

Berberine; Diabetic nephropathy; Fibrosis; Inflammation; NF B; TGF Smad signalling

Indexed keywords

ALBUMIN; BERBERINE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UREA; AUTACOID;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETIC NEPHROPATHY; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; ANIMAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; MALE; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; BERBERINE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; INFLAMMATION MEDIATORS; MALE; RATS; RATS, WISTAR;

EID: 84930358147     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12402     Document Type: Article

References (44)

1. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. 2003; 14: 1358-73.
2. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 2005; 16: S30-3.
3. Matsushita Y, Ogawa D, Wada J et al. Activation of peroxisome proliferator-activated receptor δ inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes 2011; 60: 960-8.
4. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 2008; 19: 433-42.
5. Sanz AB, Sanchez-Nino MD, Ramos AM et al. NF-kappaB in renal inflammation. J. Am. Soc. Nephrol. 2010; 21: 1254-62.
6. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: A systemic review and meta-analysis. Evid. Based Complement. Alternat. Med. 2012; 2012: 591654.
7. Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr. Metab. Immune Disord. Drug Targets 2008; 8: 99-111.
8. Lee YS, Kim WS, Kim KH et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006; 55: 2256-64.
9. Wang Y, Campbell T, Perry B, Beaurepaire C, Qin L. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet and streptozotocin-induced diabetic rats. Metabolism 2011; 60: 298-305.
10. Yin J, Xing HL, Ye JP. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008; 57: 712-7.
11. Zhang Y, Li X, Zou D et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 2008; 93: 2559-65.
12. Zhang H, Wei J, Xue R et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010; 59: 285-92.
13. Tang LQ, Liu S, Zhang ST, Zhu LN, Wang FL. Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy. Mol. Biol. Rep. 2014; 41: 3339-47.
14. Wu D, Wen W, Qi CL et al. Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine 2012; 19: 712-8.
15. Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J. Diabetes 2014; 5: 393-8.
16. Chen HY, Huang XR, Wang W et al. The protective role of Smad7 in diabetic kidney disease: Mechanism and therapeutic potential. Diabetes 2011; 60: 590-601.
17. Hong SW, Isono M, Chen S et al. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am. J. Pathol. 2001; 158: 1653-63.
18. Wang C, Li J, Lü X et al. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur. J. Pharmacol. 2009; 620: 131-7.
19. Xia X, Yan JH, Shen YF et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS ONE 2011; 6: e16556.
20. Zhang Q, Xiao X, Feng K et al. Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evid. Based Complement. Alternat. Med. 2011; 2011: 1-10.
21. Gu Y, Zhang YF, Shi XZ et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta 2010; 81: 766-72.
22. Taneja D, Thompson J, Wilson P et al. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am. J. Pathol. 2011; 179: 1179-87.
23. Li T, Yang GM, Zhu Y et al. Diabetes and hyperlipidemia induce dysfunction of VSMCs: Contribution of the metabolic inflammation/miRNA pathway. Am. J. Physiol. Endocrinol. Metab. 2015; 308: E257-69.
24. Mirmiran P, Bahadoran Z, Azizi F. Lipid accumulation product is associated with insulin resistance, lipid peroxidation, and systemic inflammation in type 2 diabetic patients. Endocrinol. Metab. (Seoul) 2014; 29: 443-9.
25. Wu L, Parthofer KG. Diabetic dyslipdemia. Metabolism 2014; 63: 1469-79.
26. Abo-elmatty DM, Essawy SS, Badr JM et al. Antioxidant and anti-inflammatory effects of Urtica pilulifera extracts in type 2 diabetic rats. J. Ethnopharmacol. 2013; 145: 269-77.
27. Dong Z, Chen CX. Effect of catalpol on diabetic nephropathy in rats. Phytomedicine 2013; 20: 1023-9.
28. Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm. 2012; 2012: 146154.
29. Roy MS, Janal MN, Crosby J, Donnelly R. Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes. Kidney Int. 2015; 87: 427-33.
30. Iwamoto M, Mizuiri S, Arita M, Hemmi H. Nuclear factor-kappa B activation in diabetic rat kidney: Evidence for involvement of P-selectin in diabetic nephropathy. Tohoku J. Exp. Med. 2005; 206: 163-71.
31. Lan T, Wu T, Chen C et al. Berberine attenuates high glucose-induced proliferation and extracellular matrix accumulation in mesangial cells: Involvement of suppression of cell cycle progression and NF-kappaB/AP-1 pathways. Mol. Cell. Endocrinol. 2014; 384: 109-16.
32. Shan J, Fu J, Zhao Z et al. Chlorogenic acid inhibits lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells through suppressing NF-kappaB and JNK/AP-1 activation. Int. Immunopharmacol. 2009; 9: 1042-8.
33. Huang K, Liu W, Lan T et al. Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models. PLoS ONE 2012; 7: e43874.
34. Lan HY. Transforming growth factor-beta/Smad signalling in diabetic nephropathy. Clin. Exp. Pharmacol. 2012; 39: 731-8.
35. Zhao TT, Zhang HJ, Lu XG et al. Chaihuang-Yishen granule inhibits diabetic kidney disease in rats through blocking TGF-β/Smad3 signaling. PLoS ONE 2014; 9: e90807.
36. Wang A, Ziyadeh FN, Lee EY et al. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am. J. Physiol. Renal. Physiol. 2007; 293: F1657-65.
37. Ka SM, Yeh YC, Huang XR et al. Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor kappa B (NF-κB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 2012; 55: 509-19.
38. Xie X, Chang X, Chen L et al. Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of RhoA/ROCK signaling. Mol. Cell. Endocrinol. 2013; 381: 56-65.
39. Wang H, Li H, Jiang X et al. Hepcidin is directly regulated by insulin and plays an important role in iron overload in streptozotocin-induced diabetic rats. Diabetes 2014; 63: 1506-18.
40. Chen HY, Zhong X, Huang XR et al. MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol. Ther. 2014; 22: 842-53.
41. Meng XM, Huang XR, Xiao J et al. Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro. J. Pathol. 2012; 227: 175-88.
42. Zhang HJ, Zhao TT, Gong YW et al. Attenuation of diabetic nephropathy by Chaihuang-Yishen granule through anti-inflammatory mechanism in streptozotocin-induced rat model of diabetics. J. Ethnopharmacol. 2014; 151: 556-64.
43. Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC. A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: Use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J. Histochem. Cytochem. 1995; 43: 97-102.
44. Yim HE, Ha KS, Bae IS et al. Overweight, hypertension and renal dysfunction in adulthood of neonatally overfed rats. J. Nutr. Biochem. 2013; 24: 1324-33.